Formulation For Anti-Alpha4Beta7 Antibody
Patent No. EP4403579 (titled "Formulation For Anti-Alpha4Beta7 Antibody") was filed by Millennium Pharmaceuticals on May 2, 2012. The application was issued on Dec 10, 2025.
Patent Summary
This stable liquid pharmaceutical formulation comprises an anti-α4β7 antibody at a concentration of approximately 60 mg/ml to 180 mg/ml, a histidine buffer, and at least 5 mM citrate. The anti-α4β7 antibody is characterized by a heavy chain variable region comprising amino acids 20 to 140 of SEQ ID NO: 2, and a light chain variable region comprising either amino acids 20 to 131 of SEQ ID NO: 4 or amino acids 21 to 132 of SEQ ID NO: 5. The formulation is designed to improve stability by reducing antibody degradation pathways, including deamidation, oxidation, isomerization, and aggregation. It may further include polysorbate 80, arginine, and is intended for the treatment of inflammatory bowel disease.
Patent Family
Patent Oppositions (4)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP4403579
- Application Number
- EP24167554A
- Filing Date
- May 2, 2012
- Status
- Granted And Under Opposition
- Nov 7, 2025
- Publication Date
- Dec 10, 2025
- External Links
- Slate, Register , Google Patents